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Summary
The strongest risk factor for prostate cancer, 
excluding age, is family history, highlighting the 
importance of heredity in the risk of prostate cancer. 
Extensive studies of prostate cancer families have led 
to the identification of mutations in three genes that 
segregate with the disease but the prevalence of 
these mutations is too low to be of clinical relevance.  
The great majority of the remaining genetic risk of 
prostate cancer is likely due to the combined effects of 
many low-to-moderate risk variants which, until 
recently, remained elusive. Breakthrough genotyping 
technologies have revolutionized the search for these 
moderate risk variants.  Here we review the results of 
a genome-wide association study of prostate cancer 
conducted by the Polygene consortium, coordinated 
by deCODE Genetics (www.polygene.eu), which has 
led to the identification of 4 common sequence 
variants that each confer a moderately increased risk 
of prostate cancer. These variants are all common and 
thus account for a substantial proportion of the 
population attributable risk (PAR) of prostate cancer.
Introduction
Epidemiological studies suggest that the genetic 
component of the risk of prostate cancer is greater 
than in any other cancer. Despite strong evidence for 
genetic factors, highly penetrant susceptibility genes 
for prostate cancer have proven difficult to find. This 
contrasts with other common cancers such as breast 
cancer, colon cancer and melanomas, where a small 
percentage of cases can be attributed to the 
inheritance of highly-penetrant mutations.  
Analysis of data from large twin studies has 
suggested that the majority of genetic prostate cancer 
risk may be attributable to recessive and/or multiple 
interacting genetic variants (1).  Each such variant 
might be expected to confer a small increase in risk 
but if the variant is common, it might contribute 
significantly to the population attributable risk (PAR). 
If this polygenic model is correct, linkage studies of 
families with multiple cases of prostate cancer would 
not suffice because they lack power to detect low-
penetrance risk variants. In order to identify such 
variants, the association approach (i.e. the 
comparison of allelic frequencies of genetic variants 
between cases and controls) has proven to be 
effective. However, this study design requires a large 
number of cases and controls to be genotyped for 
hundreds of thousands of genetic markers, an 
undertaking that, until recently, remained 
prohibitively expensive.
Lately, advances in genotyping technologies have 
Inherited risk of prostate cancer
“Population study identifies common sequence variants that increase risk of prostate cancer”
revolutionized genetic association studies of common 
diseases. Whole-genome scans using a large number 
of genetic markers in case-control study populations 
have led to an onslaught of landmark publications 
describing common genetic risk variants that affect 
complex diseases.  Notably, genome-wide association 
studies on prostate cancer have led to the 
identification of several such variants, providing a 
new perspective on this complex disease.  
“Whole-genome scans using a 
large number of genetic markers in 
case-control study populations have 
led to an onslaught of landmark 
publications describing common 
genetic risk variants that affect 
complex diseases.”
Prostate cancer risk variants on Chr8q24
Using a combination of linkage and association 
studies in the Icelandic population, we initially 
discovered a common sequence variant on 
chromosome 8q24 that is associated with a moderate 
increase in prostate cancer risk (2). This variant is 
represented by a risk-allele of a microsatellite marker 
(allele -8 of marker DG8S737), with an odds ratio (OR) 
of 1.79. A further refinement of the locus showed that 
allele A of the single-nucleotide polymorphism (SNP) 
rs1447295 also showed a significant association with 
prostate cancer (OR=1.72).  
We replicated these results in three additional 
cohorts, two of European origin and one African 
American cohort, demonstrating that the risk variants 
may confer considerable PAR in both Europe and the 
U.S., which are the regions of the world that have the 
highest incidence of prostate cancer. Combining the 
results from all the populations gave an OR of 1.62 for 
allele -8 of DG8S737 and 1.51 for allele A of rs1447295. 
We have subsequently replicated the associations of 
DG8S737 and rs1447295 to prostate cancer in Spanish 
and Dutch case-control samples (3) and several 
independent groups have also reported similar results 
as well as several additional variants in this region. 
Hereafter, we refer to the genomic region containing 
DG8S737 and rs1447295 as region 1.
Interestingly, while both DG8S737 and rs1447295 were 
associated with cancer in populations of European 
descent, only DG8S737 was associated with prostate 
cancer in African Americans. In this population, allele 
-8 of DG8S737 is present in 41% of cases and 30% of 
controls or at a frequency twice as high as in the 
European populations. This large difference may be 
partly responsible for the higher incidence of prostate 
cancer observed in African Americans than in 
Europeans. The frequency of the variants in region 1 
was greater in affected individuals with high (7–10) 
compared with low (2–6) Gleason scores in all four 
case control groups, suggesting that the variant may 
be associated with an aggressive form of the disease.
After we reported the initial 8q24 findings, we 
conducted a genome-wide association study on 1,453 
prostate cancer patients and 3,064 controls from 
Iceland using 317,000 genetic markers, followed by 
replication studies in three populations of European 
descent, as well as African Americans. The strongest 
signal detected in this genome-wide scan was the 
rs1447295 variant we had reported earlier. 
Subsequently, we identified a second novel genetic 
variant in the 8q24 region that was defined by a 14 
SNP haplotype (HapC) and had an OR of 2.08 (4). 
However, the frequency of HapC was considerably 
lower than that of the rs1447295 variant, or 3% in 
Icelandic controls compared to 10.4% for rs1447295. 
By examining the HapMap data and later by further 
genotyping in the Icelandic study group, allele A of 
the SNP rs16901979 was shown to be strongly 
correlated with HapC as well as associated with 
prostate cancer (OR = 1.80). Both the results for HapC 
and the correlated SNP were replicated in case-
control samples of European descent from the 
Netherlands, Spain and the US. The combined OR for 
allele A of rs16901979 in the three populations was 
about 1.8. The SNP was significantly associated with 
prostate cancer in African Americans with an OR of 
1.34 and similarly to the variants in region 1, the 
frequency was found to be considerably higher (~10-
times) than that of the European population. Again, 
our findings have been independently verified in 
other studies (5).
Contrary to the first region, no evidence was found for 
a stronger association between HapC and disease in 
individuals with a higher Gleason score. However, for 
each copy of allele A of rs16901979, carriers were 
diagnosed with prostate cancer 1.4 years younger 
than the non-carriers; HapC gave very similar results. 
Based on this observation and the fact that familial 
cancer cases tend to have younger age at diagnosis, it 
is not surprising that the frequency of allele A of 
rs16901979 is greater in individuals who have at least 
one first- or second-degree relative with prostate 
cancer compared with cases that have no closely 
related relative diagnosed with prostate cancer (OR of 
1.6) (unpublished results).
The two genomic regions on 8q24 demonstrating 
association with prostate cancer are in a gene-poor 
area characterized by a high recombination rate of 
~2 cM/Mb, compared to the genome-wide average of 
1.2 cM/Mb. The only reported “known gene” in the 
interval defined by these two regions (spanning 
~550kb) is a retrotransposed gene named AF268618 
(POU5FLC20) (www.genome.ucsc.edu, May 2004 
Assembly). Two known genes, FAM84B/NSE2 and 
c-MYC are located on either side of this interval but 
we observed no association between variants of these 
genes and prostate cancer. Thus the functional 
relevance of the genetic variants remains to be 
elucidated. A number of explanations can be 
proposed, e.g. the function may be conferred by long-
range regulatory elements that affect c-MYC, the 
region may harbour regulatory transcripts or viral and 
transposon integration sites, or may be particularly 
sensitive to chromosome breakage. In this regard it is 
important to note that chromosome 8q24 is the most 
commonly gained or amplified genomic region in 
prostate tumours, as well as in a number of other 
cancers.
Prostate cancer risk variants on Chr17q
Based on our experience with chromosome 8q24, we 
anticipated that results from family-based linkage 
studies could be used to guide the evaluation of 
results of a genome-wide association study. Using 
this approach, we identified two common variants in 
two distinct regions on the long arm of chromosome 
17 that confer risk of prostate cancer (4). One locus is 
on 17q12, encompassing the 5’ end of the TCF2 
(HNF1β) gene (represented by rs7501939 and 
rs4430796) while the second locus is in a gene poor 
area on 17q24.3 (represented by rs1859962). Both risk 
variants are present in high frequency as about 24% 
of the populations are homozygous for the variant at 
17q12 and 21% are homozygous for the variant at 
17q24.3. In the homozygous state, both variants confer 
an OR between 1.4 and 1.5. The two loci are separated 
by approximately 33 Mb and no correlation was 
observed between them. Based on the combined 
results from the four study populations, the two 
variants on 17q have an estimated PAR of 20% each, 
and a joint PAR of about 36%. The large PAR is a 
consequence of the high frequencies of these variants. 
However, as their relative risks are not high, the 
sibling risk ratio accounted for by them is only 
approximately 1.009 each, and 1.018 jointly. Therefore, 
they can only explain a small fraction of the familial 
clustering of the disease.
“It is therefore unlikely that any 
single variant will be of clinical 
value alone. However, the combined 
effect of these and other prostate 
cancer risk factors may provide a 
sufficiently high predictive value to 
become clinically important.”
The TCF2 gene on 17q12 has been reported to be 
mutated in individuals diagnosed with renal cysts, 
pancreatic atrophy, genital tract abnormalities, and 
maturity-onset diabetes of the young, type 5 (MODY5) 
(6, 7). Interestingly, several epidemiological studies 
have demonstrated an inverse relationship between 
type 2 diabetes (T2D) and the risk of prostate cancer 
(8). When the effect of the two SNPs in TCF2 were 
studied in an Icelandic T2D case-control group as well 
as in seven additional T2D case-control groups of 
African-, Asian- and European descent, both SNPs 
showed a protective effect against the disease (i.e. OR 
< 1.0). The discovery of variants in TCF2 that confer 
risk of prostate cancer but protect against T2D 
explains at least partly the inverse relationship 
previously described between the two diseases. A 
more detailed study of the function of TCF2 may 
possibly lead to the identification of mutual 
pathway(s) that could provide better diagnostic and/
or therapeutic options for both diseases.
Concluding remarks
Four common sequence variants have been identified 
that have a significant impact on prostate cancer 
susceptibility. Three of them are common (>5% freq.) 
and they all confer low to moderate relative risk of 
1.2 - 2. It is therefore unlikely that any single variant 
will be of clinical value alone. However, the combined 
effect of these and other prostate cancer risk factors 
may provide a sufficiently high predictive value to 
become clinically important.
Intriguingly, three of the four variants are located in 
regions with no annotated genes while the fourth one 
is in TCF2, a gene not previously implicated in 
prostate cancer. The fact that the majority of the 
variants discovered so far are not close to known 
genes is striking but evidence is mounting that 
prostate cancer does not present a unique case in this 
respect. Several high-density genome wide SNP 
association analyses have been done for some of the 
most frequently diagnosed cancers such as prostate, 
breast and colon cancer. Results from these studies 
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deCODE genetics uses a population approach to unravel the genetic causes of common diseases.  The company’s prostate cancer 
program has identified 4 sequence variants that impact the risk of developing prostate cancer.
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indicate that a sizeable fraction of variants that 
associate with disease status do not fall within 
protein-coding genes. Thus, in order to understand 
the causal link between non-gene risk variants and 
disease, focused genomic approaches have to be 
undertaken to characterize in detail the regions over 
and around the signals with regard to transcribed 
sequences, structural properties and genomic 
stability.
In summary, genome-wide association analysis done 
in a population based case-control samples 
demonstrate that low-to-moderate risk variants 
contribute significantly to the overall prostate cancer 
susceptibility. However, the variants discovered to 
date do not make a large contribution to the familial 
clustering of prostate cancer. Hence, additional 
susceptibility variants remain to be identified.
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The recently introduced Clinical challenge section 
presents interesting or difficult clinical problems 
which in a subsequent issue of EUT will be discussed 
by experts from different European countries as to 
how they would manage the problem.
Clinical challenge
A 46-year-old man was referred by a urologist 
from a small hospital with the diagnosis of 
advanced testicular cancer. 
The patient had a huge left-sided scrotal solid 
mass of 15 cm in diameter. CT scan showed 
retroperitoneal lymph node enlargement (see 
figure, 12x6x7 cm), smaller left-sided pelvic 
masses, a small hydronephrotic left kidney but no 
pulmonary or mediastinal masses. The patient 
admitted to having noticed an enlarging painless 
scrotal swelling for up to 12 months, recently 
intermittent scrotal pain, constant back and 
epigastral pain as well as a weight loss of about 
30 kg over the last 6 months. There was no 
dyspnea. The patient was a self-employed truck 
driver living with a girl-friend and two children 
from a previous marriage.
Serum creatinin was 88 μmol/L, hemoglobin 8,2 
mmol/L, C-reactive protein 233 mg/L, 
a-fetoprotein (AFP) 1,6 IU/mL (normal < 8.3), 
ß-human chorionic gonadotropin (HCG) 145 mIU/
mL (< 5), serum lactate dehydrogenase (LDH) 369 
U/L (<250) and human placental alkaline 
phospatase (PLAP) > 1000 mU/L (< 100).
A percutaneous nephrostomy was inserted into 
the left kidney which drained clear urine. 
Inductive chemotherapy consisting of etoposide, 
bleomycine and cisplatinum (PEB) was 
commenced. One week later, left sided radical 
orchiectomy was performed and a 14x10x10 cm 
testicle removed with infiltration of the spermatic 
cord up to the internal inguinal ring which was 
pathologically staged as pT3R0 and classified as a 
largely necrotic anaplastic seminoma. 
Immunohistochemistry showed positive PLAP, c-
KIT and MIB1 reactions and negativity for AFP, 
CD30 and ß-HCG. 
Three full courses of PEB were given which were 
well tolerated, nausea could be controlled 
pharmacologically and two episodes of 
asymptomatic neutropenia passed uneventfully. 
Secondary wound healing occurred but resolved 
with local treatment. A repeat CT scan showed 
marked regression of the retroperitoneal masses 
(9x3x3 cm) and the nephrostomy was removed. At 
the beginning of the 3rd course of chemotherapy 
AFP had been 3,39 IU/mL (normal < 8.3), ß-HCG 
1,16 mIU/mL (< 5), LDH 102 U/L (<250) and PLAP 
<0.1 mU/L (< 100). At the completion of the third 
course, AFP had increased to 16.7 IU/mL (normal < 
8.3), ß-HCG <0.1 mIU/mL (< 5), LDH 545 U/L (<250) 
and human placental AP was 57 mU/L (< 100).
CT scan before the beginning of systemic treatment.
Discussion points
1. What is going on?
2. Are our guidelines helpful in this situation?
3. What further treatment would you advise?
4. What is the patient’s prognosis?
Case provided by Oliver Hakenberg, Dept. of 
Urology, Rostock University, Germany
oliver.hakenberg@med.uni-rostock.de
The initial presentation 
suggested a stage IIC 
seminoma of the left 
testis (IGCCCG 
classification “good 
prognosis”). However, 
the prechemotherapy 
CT scan of the 
abdomen showed that 
the suspicious large 
mass in the abdomen 
is mainly at the right 
side, precaval, extending into the mesentery. 
Since the bowel and vena cava contrast is not 
optimal on this CT slice, the extension of the mass 
is hard to evaluate (12x6x7 cm in the text). 
The metastases at the typical landing zone (left 
paraaortal) are comparatively small (about 3 cm 
in transverse diameter of the given CT slice). This 
left retroperitoneal mass correlates perfectly with 
the serum levels of HCG and LDH which are only 
moderately elevated. PLAP is not of additional 
use. It remains unclear why the left kidney is 
hydronephrotic with only moderate metastases at 
the left retroperitoneum (perhaps due to the 
pelvic metastases that are not shown). 
The clinical response to the adequately applied 3 
cycles of BEP (according to “good prognosis” 
IGCCCG) is insufficient regarding the large right-
sided precaval mass. In seminoma we expect a 
major response to chemotherapy and usually a 
shrinkage of >90% of the initial metastatic 
volume. This was true for the left side since the 
nephrostomy tube could be removed and this was 
reflected in the markers which normalized. The 
right sided mass, however, did not respond 
adequately to 3 cycles BEP with a reduction of 
only 30-40% of volume (pictures not shown). In 
summary, the localisation of the larger volume 
metastatic disease and the response to 
chemotherapy did not fit to a typically left-sided 
metastatic seminoma. In addition, the weight loss 
with 30 kg over 6 ms is not really typical for a 
stage IIC metastatic seminoma patient at the age 
of 46 years.
After 3 cycles of BEP, AFP and LDH start to rise (2x 
N) with HCG remaining normal. The normalisation 
of HCG in a HCG-expressing metastatic seminoma 
usually is a good clinical sign of adequate 
treatment response of the seminoma cells. No 
information is given on the size of the residual 
right-sided mass at this time. 
The clinical suspicion is that this mass has a 
different histology, perhaps even non-germ cell 
origin. I would therefore try to get a histology, 
preferably by open surgery, for two reasons: CT 
guided biopsy is not representative and at this 
special location not easy to perform. False-
positive AFP elevations (e.d. due to altered liver 
function or infections) are possible but in this case 
unlikely since LDH is elevated as well. 
Further treatment is strongly dependent on the 
histology of the residual mass. Without histology I 
would not start salvage chemotherapy because a 
non-germ cell tumor is not excluded. The 
prognosis is dependent on the histology of the 
residual mass and the possible treatment options.
Case history continued by Oliver Hakenberg, 
Rostock (DE)
Given the insufficient response in conjunction 
with a rising AFP and LDH we assumed that 
the histological assessment of the largely 
necrotic primary testicular tumour had not 
been representative and that we were dealing 
with a metastatic non-seminoma. A fourth 
cycle of BEP chemotherapy was undertaken. 
However, towards the end of this fourth cycle 
the patient presented with marked jaundice 
and ascites. 
All liver function tests were markedly elevated 
(ALAT/SGPT1685 U7L (normal < 50), ASAT/SGOT 
1492 U/L (normal < 50), LDH 328 U/l, total 
bilirubine 383 μmol/l (normal < 22). 
Intrahepatic and extrahepatic cholestatsis 
were excluded by sonograohy and CT scan. 
Serologic investigations and repeated liver 
biopsy revealed an active hepatitis B together 
with an alcoholic liver degeneration with 
cirrhotic changes. The patient developed 
progressive hepatic failure despite supportive 
and substitution treatment in addition to a 
course of hepatic dialysis by MARS treatment 
which was uneffective. 
Two months after the presentation with 
jaundice the patient died of progressive 
hepatic and renal failure.     
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Case study 2 - Renal cell carcinoma
A 50-year old man presented with a lumbar painful 
mass. The patient had first noticed mild lumbar left 
sided pain 5 months previously. Treatment by the 
general practitioner and orthopedic physician had 
first been based on the assumption of chronic back 
pain due to degenerative lumbar problems. 
Antiphlogistic medication had been effective for some 
time. 
With time, however, pain increased and became 
constant and independent of movement or posture 
and the patient noticed a palpable left-sided lumbar 
‘hardness’. MR imaging showed a 12x10 cm lumbar 
mass arroding the dorsal iliac crest and invading the 
lateral and dorsal musculature (see figure).
The patient had undergone left-sided laparoscopic 
radical nephrectomy for a renal cell carcinoma staged 
as pT1cN0cM0G2 just under two years previously. In 
view of this fact and the new finding the patient was 
now referred to the Urology Department.
On examination, the left sided lumbar tumour was 
clearly palpable, not mobile and not painful to touch 
and there were no local or systemic signs of 
inflammation. Sonographically guided percutaneous 
biopsy was performed with a true-cut needle. 
Histology confirmed malignant tissue in all cores 
compatible with the metastasis of a renal cell 
carcinoma. 
Local pain is still mild to moderate and well controlled 
by analgesic first-line medication (diclofenac 50 mg 
b.i.d.). Apart from this problem, the patient is in good 
health, without any comorbidity. Extensive further 
staging by CT, MRI and bone scan did not show any 
other signs of metastatic disease.  
 
Discussion points
1. What treatment options can be offered?
2.  What is a good management strategy for this 
patient?
3. What is the patient’s prognosis?
Case provided by Oliver Hakenberg, Dept. of Urology, 
Rostock University, Germany
oliver.hakenberg@med.uni-rostock.de
Readers are encouraged to provide interesting and 
challenging cases for discussion
MRI image of the left-sided lumbar tumour (frontal view at the 
level of the spinal musculature)
Prof.Dr. P. Albers
Kassel (DE)
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